Evidence map›Paper›PMID 35066955›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2022

Superior effect of MP-AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP-1 and TTP anti-inflammatory gene expression in healthy and inflamed upper airway mucosa.

Sònia Vicens-Artés, Jordi Roca-Ferrer, Valeria Tubita, Mireya Fuentes, Isam Alobid, Antonio Valero, Ferdinand Kopietz, DucTung Nguyen, Joaquim Mullol

Open access · hybridAbstract readLetter
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Sònia Vicens-ArtésClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Jordi Roca-FerrerClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Valeria TubitaClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Mireya FuentesClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Isam AlobidClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Antonio ValeroClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Ferdinand KopietzMEDA Pharma GmbH & Co. KG (A Viatris Company), Bad Homburg, Germany.
DucTung NguyenMEDA Pharma GmbH & Co. KG (A Viatris Company), Bad Homburg, Germany.
Joaquim MullolClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESMeda (Germany) · DEUniversitat de Barcelona · ESCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Inflammatory AgentsMucous MembraneAndrostadienesDrug CombinationsFluticasoneGene ExpressionHumansPhthalazinesAndrostadienesAnti-Inflammatory AgentsazelastineDrug CombinationsFluticasonePhthalazinesazelastinefluticasonegene expressionGILZMKP-1MP-AzeFluTTP

Identifiers

PMID35066955
PMCPMC9305966
OpenAlexW4207049740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.